Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Export

@article{citeulike:754262, abstract = {Multiple sclerosis (MS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are chronic, immune-mediated, relapsing-remitting disorders affecting young adults, the pathogenesis of which is still largely unknown. Neurological manifestations and magnetic resonance imaging (MRI) can be indistinguishable and there are no specific diagnostic tools. Treatment and prognosis are quite different. There is controversy about the prevalence and significance of antiphospholipid antibodies (aPL) in MS. A significant number of patients with APS/SLE are misdiagnosed as MS but evidence suggests they are distinct nosological entities. However, it is essential to differentiate them since APS may be responsive to anticoagulation. When assessing MS patients, clinicians should consider APS/SLE, especially if the MS has atypical features. A trial of anticoagulation might be worthwhile in some patients with atypical MS and consistently positive aPL.}, address = {Internal Medicine Department (B), S. Jo\~{a}o Hospital, Alameda Prof. Hern\^{a}ni Monteiro, Porto, Portugal.}, author = {Ferreira, S. and D'Cruz, D. P. and Hughes, G. R.}, citeulike-article-id = {754262}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/15644391}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=15644391}, issn = {1462-0324}, journal = {Rheumatology (Oxford)}, keywords = {esclerose\_multipla, lupus}, month = {April}, number = {4}, pages = {434--442}, posted-at = {2006-07-12 04:25:00}, priority = {2}, title = {Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand?}, url = {http://view.ncbi.nlm.nih.gov/pubmed/15644391}, volume = {44}, year = {2005} }

TY - JOUR ID - citeulike:754262 L3 - citeulike-article-id:754262 N2 - Multiple sclerosis (MS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are chronic, immune-mediated, relapsing-remitting disorders affecting young adults, the pathogenesis of which is still largely unknown. Neurological manifestations and magnetic resonance imaging (MRI) can be indistinguishable and there are no specific diagnostic tools. Treatment and prognosis are quite different. There is controversy about the prevalence and significance of antiphospholipid antibodies (aPL) in MS. A significant number of patients with APS/SLE are misdiagnosed as MS but evidence suggests they are distinct nosological entities. However, it is essential to differentiate them since APS may be responsive to anticoagulation. When assessing MS patients, clinicians should consider APS/SLE, especially if the MS has atypical features. A trial of anticoagulation might be worthwhile in some patients with atypical MS and consistently positive aPL. IS - 4 JF - Rheumatology (Oxford) SN - 1462-0324 AD - Internal Medicine Department (B), S. João Hospital, Alameda Prof. Hernâni Monteiro, Porto, Portugal. EP - 442 TI - Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? VL - 44 SP - 434 KW - esclerose_multipla KW - lupus AU - Ferreira, S AU - D'Cruz, DP AU - Hughes, GR PY - 2005/04// UR - http://view.ncbi.nlm.nih.gov/pubmed/15644391 ER -